GlassScriptPhysician profile
Kathryn C Thelen
NPI 1104209337
$4,041.01
in general payments reported to CMS, 2019-2025
35 companies · $957 in 2025
The $957 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $528 · 2021: $807 · 2022: $403 · 2023: $416 · 2024: $674 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,174.81 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $969.19 | 2020-2025 | Vraylar, Botox, Ubrelvy |
| Novo Nordisk INC | $430.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $127.91 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $127.87 | 2024-2025 | Zenpep |
| Pfizer INC. | $123.47 | 2019-2025 | |
| Abbott Laboratories | $100.88 | 2023-2025 | Freestyle Libre 3, Cardiomems |
| Janssen Pharmaceuticals, INC | $78.01 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $76.64 | 2021-2024 | Rexulti |
| Astellas Pharma US INC | $76.55 | 2019-2025 | Veozah |
| Medtronic, INC. | $67.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.62 | 2020 | |
| Lilly USA, LLC | $54.88 | 2021-2022 | |
| Allergan, INC. | $50.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.29 | 2020-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $45.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.78 | 2019-2021 | |
| Philips North America LLC | $44.38 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.03 | 2025 | Caplyta |
| Organon LLC | $29.56 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $28.74 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.64 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $26.84 | 2019-2021 | |
| Esperion Therapeutics, INC. | $26.63 | 2020 | |
| Nestle Healthcare Nutrition INC. | $22.42 | 2021 | |
| Boston Scientific Corporation | $19.86 | 2025 | Bodyguardian |
| Seqirus USA INC | $18.66 | 2025 | Flucelvax, Fluad |
| Roche Diagnostics Corporation | $15.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.58 | 2021 | |
| Amarin Pharma, INC. | $15.50 | 2020 | |
| Inspire Medical Systems, INC. | $15.34 | 2024 | Inspire |
| Alkermes, INC. | $12.97 | 2023 | Lybalvi |
| Lundbeck LLC | $11.46 | 2020 | |
| Genentech USA, INC. | $11.42 | 2020 | |
| Phathom Pharmaceuticals, INC. | $4.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Thelen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.